LEADER 02915nam 2200637 450 001 9910788882303321 005 20170821172555.0 010 $a1-4704-0738-8 035 $a(CKB)3360000000464533 035 $a(EBL)3113918 035 $a(SSID)ssj0000888871 035 $a(PQKBManifestationID)11480047 035 $a(PQKBTitleCode)TC0000888871 035 $a(PQKBWorkID)10864963 035 $a(PQKB)10618531 035 $a(MiAaPQ)EBC3113918 035 $a(RPAM)2859014 035 $a(PPN)195412060 035 $a(EXLCZ)993360000000464533 100 $a20140905h19851985 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aDeformations of nilpotent matrices over rings and reduction of analytic families of meromorphic differential equations /$fDonald G. Babbitt and V.S. Varadarajan 210 1$aProvidence, Rhode Island :$cAmerican Mathematical Society,$d1985. 210 4$dİ1985 215 $a1 online resource (157 p.) 225 1 $aMemoirs of the American Mathematical Society,$x0065-9266 ;$vNumber 325 300 $a"May 1985, volume 55, number 325 (first of 2 numbers)." 311 $a0-8218-2326-4 320 $aIncludes bibliographical references. 327 $a""CONTENTS""; ""1. INTRODUCTION""; ""NILPOTENT MATRICES OVER INTEGRAL DOMAINS: STRUCTURE AND DEFORMATION""; ""2. The invariants l[sub(j)]""; ""3. Local deformations of endomorphisms and modules over discrete valuation rings""; ""4. Upper semicontinuity of l. Structure of deformations with constant l.""; ""5. Admissible nilpotents and their transversal deformations""; ""REDUCTION THEORY OF CONNECTIONS OVER INTEGRALLY CLOSED NOETHERIAN DOMAINS""; ""6. Generalities and preliminaries""; ""7. Connections over Dedekind domains"" 327 $a""8. The general case: reduction in the category of differential modules""""REDUCTION OF CONNECTIONS OVER I??[sub(d)]""; ""9. The main theorem for well-behaved connections over I??[sub(d)]""; ""10. Reduction of regulated connections""; ""APPENDIX""; ""REFERENCES"" 410 0$aMemoirs of the American Mathematical Society ;$vNumber 325. 606 $aDifferential equations, Linear 606 $aFunctions, Meromorphic 606 $aSingularities (Mathematics) 606 $aMatrices 606 $aRings (Algebra) 615 0$aDifferential equations, Linear. 615 0$aFunctions, Meromorphic. 615 0$aSingularities (Mathematics) 615 0$aMatrices. 615 0$aRings (Algebra) 676 $a515.3/54 700 $aBabbitt$b Donald G.$0322822 702 $aVaradarajan$b V. S. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910788882303321 996 $aDeformations of nilpotent matrices over rings and reduction of analytic families of meromorphic differential equations$93696180 997 $aUNINA LEADER 04118nam 22004935 450 001 9910254496803321 005 20200707023718.0 010 $a3-319-40347-8 024 7 $a10.1007/978-3-319-40347-2 035 $a(CKB)3710000000765389 035 $a(DE-He213)978-3-319-40347-2 035 $a(MiAaPQ)EBC4616185 035 $a(PPN)194517152 035 $a(EXLCZ)993710000000765389 100 $a20160728d2017 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCardiovascular Safety in Drug Development and Therapeutic Use $eNew Methodologies and Evolving Regulatory Landscapes /$fby J. Rick Turner, Dilip R. Karnad, Snehal Kothari 205 $a1st ed. 2017. 210 1$aCham :$cSpringer International Publishing :$cImprint: Adis,$d2017. 215 $a1 online resource (XXVI, 333 p. 2 illus. in color.) 311 $a3-319-40345-1 320 $aIncludes bibliographical references at the end of each chapters. 327 $aThe Central Importance of Cardiovascular Safety in Contemporary New Drug Development -- The Biological Basis of Drug Responses -- Cardiovascular Structure, Function, Pathophysiology, & Disease -- The Current Regulatory Landscape -- The "Comprehensive In Vitro Proarrhythmia Assay" Initiative -- The "Early ECG Assessment" Initiative -- The "Submission of Extended Digital ECG Data" Initiative -- Meta-analysis and Meta-methodology -- Current Regulatory Landscapes and their Potential Evolution -- Off-target Blood Pressure Responses to Non-cardiovascular Drugs -- Oncology Drug Development and Therapeutics: Cardiotoxicity Considerations -- Postmarketing Surveillance -- Regulatory Perspectives on General Drug Safety -- Future Directions in Cardiovascular Safety -- References. 330 $aWith the advent of multiple new therapeutic agents for a variety of important diseases has come an increasing realization that many of these drugs can have adverse effects on the heart and vascular system. As this book so elegantly details the mechanisms by which harm occurs are highly complex, many times predictable, but always clinically relevant. Notable experts in the field of cardiovascular medicine, such as Drs. Turner, Karnad, and Kothari, have turned their attention to this thorny problem, and begun to dissect the diverse mechanisms by which cardiac harm can occur with a variety of non-cardiac drugs. This is no easy task, given the complexity of the diseases we treat, and the wide spectrum of new therapies we seek to apply. However, it is an issue with which all health care providers must become familiar in order to prescribe appropriate therapy while safeguarding patients against avoidable and life-threatening cardiac adverse effects. This compendium represents the state-of-the-art in the evolving field of cardiac safety and is vital reading for those interested in developing new chemical entities, as well as those who prescribe them and monitor patients for their hazard. As such, I recommend this book as essential reading for students, scientists, and health care providers at all levels of training. Peter R. Kowey, MD, FACC, FAHA, FHRS Lankenau Institute for Medical Research & Thomas Jefferson University. 606 $aPharmacy 606 $aCardiology 606 $aDrug Safety and Pharmacovigilance$3https://scigraph.springernature.com/ontologies/product-market-codes/H69010 606 $aCardiology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33037 615 0$aPharmacy. 615 0$aCardiology. 615 14$aDrug Safety and Pharmacovigilance. 615 24$aCardiology. 676 $a353.998 700 $aTurner$b J. Rick$4aut$4http://id.loc.gov/vocabulary/relators/aut$0281064 702 $aKarnad$b Dilip R$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aKothari$b Snehal$4aut$4http://id.loc.gov/vocabulary/relators/aut 906 $aBOOK 912 $a9910254496803321 996 $aCardiovascular Safety in Drug Development and Therapeutic Use$92501455 997 $aUNINA